AUTL
Autolus Therapeutics plc
AUTL • NASDAQ
Autolus Therapeutics plc is a biological products, (no disgnostic substances) company trading on NASDAQ, led by CEO Christian Martin Itin.
CEOChristian Martin Itin
Next Earnings
Upcoming earnings announcement for Autolus Therapeutics plc
Date
Thursday, May 7, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.27
Revenue Estimate
$27.6M
Earnings History
Past 12 earnings reports for Autolus Therapeutics plc
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Q4 2025 | -$0.34Est: -$0.38 | +10.5% | $24.3MEst: $23.2M | +4.5% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$0.30Est: -$0.23 | -30.4% | $21.2MEst: $22.5M | -5.7% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.18Est: -$0.24 | +25.0% | $20.9MEst: $13.6M | +54.1% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.26Est: -$0.26 | 0.0% | $9.0MEst: $1.6M | +464.9% | 10-Q |
| Mar 20, 2025 | Q4 2024 | -$0.09Est: -$0.24 | +62.5% | $29.0KEst: $3.0M | -99.0% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.31Est: -$0.21 | -47.6% | -Est: $130.0K | -100.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.22Est: -$0.19 | -15.8% | -Est: $60.0K | -100.0% | 10-Q |
| May 16, 2024 | Q1 2024 | -$0.24Est: -$0.05 | -380.0% | $10.1MEst: $25.0M | -59.6% | 10-Q |
| Mar 14, 2024 | Q4 2023 | -$0.45Est: -$0.25 | -80.0% | - | — | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.26Est: -$0.25 | -4.0% | $406.0KEst: $450.0K | -9.8% | — |
| Aug 3, 2023 | Q2 2023 | -$0.26Est: -$0.22 | -18.2% | -Est: $140.0K | -100.0% | — |
| May 4, 2023 | Q1 2023 | -$0.23Est: -$0.27 | +14.8% | $1.3MEst: $350.0K | +269.1% | — |